UCB chief executive to chair IMI
pharmafile | March 12, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | IMI, Roch, UCB
UCB has confirmed that its chief executive Roch Doliveux has been appointed chairman of the governing board of the Innovative Medicines Initiative (IMI).
The IMI is a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
UCB has been involved in IMI since its initiation and Doliveux joined the IMI governing board in May 2010. IMI currently funds 30 projects with a combined budget of around €600 million and covering drug safety and efficacy, knowledge management, and education & training.
Doliveux said: ”The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs and bring safer, more efficacious and cost-effective treatments to patients. EFPIA considers IMI as a key instrument to implement the new business models which will ensure the sustainability of the pharmaceutical industry and increase the wellbeing of patients across Europe.’’
Executive director of IMI, Michel Goldman, said: “IMI will greatly benefit from the leadership and patient-centric perspective of Roch Doliveux. As chair of the IMI governing board, Roch will be in a unique position to move forward his vision for the future of the pharmaceutical industry based on open innovation and precompetitive research.
“The early achievements of the ongoing IMI projects demonstrate that this new model based on public-private partnership is already successful.”
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
